RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.

ABSTRACT:

Rationale

Lung cancer is a series of gene-driven disease. EGFR, ALK, and ROS1 are 3 major driver genes that play an important role in lung cancer development and precision management. Additionally, rare genetic alterations continue to be discovered and may become novel targets for therapy. The RET gene is one of such rare genetic alteration of non-small cell lung cancer (NSCLC). In this report, we present a RET-positive case that benefited from cabozantinib treatment.

Patient concern

A 50-year-old male patient was diagnosed with lung adenocarcinoma 2 years ago, at that time he received palliative surgery of pulmonary carcinoma and completed 4 cycles of chemotherapy with gemcitabine and cisplatin. Six months later, he was hospitalized in our cancer center due to the disease r

SUBMITTER: Wang Y 

PROVIDER: S-EPMC6370068 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature